131 related articles for article (PubMed ID: 12796244)
1. Perinatal outcome following third-trimester exposure to paroxetine: an alternative interpretation.
Pryse-Phillips W; Yuen DE; Pham B
Arch Pediatr Adolesc Med; 2003 Jun; 157(6):601. PubMed ID: 12796244
[No Abstract] [Full Text] [Related]
2. Perinatal outcome following third trimester exposure to paroxetine.
Costei AM; Kozer E; Ho T; Ito S; Koren G
Arch Pediatr Adolesc Med; 2002 Nov; 156(11):1129-32. PubMed ID: 12413342
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
[TBL] [Abstract][Full Text] [Related]
4. [Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine].
Salvia-Roigés MD; Garcia L; Goncé-Mellgren A; Esqué-Ruiz MT; Figueras-Aloy J; Carbonell-Estrany X
Rev Neurol; 2003 Apr 16-30; 36(8):724-6. PubMed ID: 12717649
[TBL] [Abstract][Full Text] [Related]
5. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.
Gentile S; Bellantuono C
J Clin Psychiatry; 2009 Mar; 70(3):414-22. PubMed ID: 19254517
[TBL] [Abstract][Full Text] [Related]
6. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.
Warburton W; Hertzman C; Oberlander TF
Acta Psychiatr Scand; 2010 Jun; 121(6):471-9. PubMed ID: 19878137
[TBL] [Abstract][Full Text] [Related]
7. Neonate characteristics after maternal use of antidepressants in late pregnancy.
Källén B
Arch Pediatr Adolesc Med; 2004 Apr; 158(4):312-6. PubMed ID: 15066868
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
Kulin NA; Pastuszak A; Sage SR; Schick-Boschetto B; Spivey G; Feldkamp M; Ormond K; Matsui D; Stein-Schechman AK; Cook L; Brochu J; Rieder M; Koren G
JAMA; 1998 Feb; 279(8):609-10. PubMed ID: 9486756
[TBL] [Abstract][Full Text] [Related]
9. Neonatal signs following exposure to SSRIs.
Hashimoto K
Hum Psychopharmacol; 2005 Oct; 20(7):522. PubMed ID: 16184524
[No Abstract] [Full Text] [Related]
10. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?
Bérard A
Birth Defects Res A Clin Mol Teratol; 2010 Mar; 88(3):171-4. PubMed ID: 19950383
[No Abstract] [Full Text] [Related]
11. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn.
Hallberg P; Odlind V; Sjöblom V
N Engl J Med; 2006 May; 354(20):2188-90; author reply 2188-90. PubMed ID: 16710910
[No Abstract] [Full Text] [Related]
12. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels.
Knoppert DC; Nimkar R; Principi T; Yuen D
Ther Drug Monit; 2006 Feb; 28(1):5-7. PubMed ID: 16418684
[TBL] [Abstract][Full Text] [Related]
13. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.
Bakker MK; Kölling P; van den Berg PB; de Walle HE; de Jong van den Berg LT
Br J Clin Pharmacol; 2008 Apr; 65(4):600-6. PubMed ID: 17953715
[TBL] [Abstract][Full Text] [Related]
14. Does paroxetine cause cardiac malformations?
O'Brien L; Einarson TR; Sarkar M; Einarson A; Koren G
J Obstet Gynaecol Can; 2008 Aug; 30(8):696-701. PubMed ID: 18786292
[TBL] [Abstract][Full Text] [Related]
15. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant.
Nordeng H; Spigset O
Drug Saf; 2005; 28(7):565-81. PubMed ID: 15963005
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine exposure during pregnancy and cardiac malformations.
Scialli AR
Birth Defects Res A Clin Mol Teratol; 2010 Mar; 88(3):175-7. PubMed ID: 20175190
[No Abstract] [Full Text] [Related]
17. First trimester exposure to paroxetine and prevalence of cardiac defects: Meta-analysis of the literature: Unfortunately incomplete.
Einarson A; Koren G
Birth Defects Res A Clin Mol Teratol; 2010 Jul; 88(7):588; author reply 589. PubMed ID: 20602457
[No Abstract] [Full Text] [Related]
18. Neonatal complications after intrauterine exposure to SSRI antidepressants.
Prescrire Int; 2004 Jun; 13(71):103-4. PubMed ID: 15233148
[TBL] [Abstract][Full Text] [Related]
19. Defective alleles may not have contributed to adverse effects.
Einarson A; Koren G
Ther Drug Monit; 2006 Feb; 28(1):142-3; author reply 143. PubMed ID: 16418711
[No Abstract] [Full Text] [Related]
20. Risk of fetal anomalies with exposure to selective serotonin reuptake inhibitors.
Grush LR
JAMA; 1998 Jun; 279(23):1873. PubMed ID: 9634252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
